Alkermes (ALKS) Asset Writedowns and Impairment (2012 - 2013)
Alkermes (ALKS) reported Asset Writedowns and Impairment of $3.3 million for Q3 2013, down 27.26% year-over-year from $4.6 million in Q3 2012, and little changed quarter-over-quarter from $3.3 million in Q2 2013.
Alkermes (ALKS) Asset Writedowns and Impairment (2012 - 2013) Analysis & Trends
Alkermes (ALKS) has 2 years of Asset Writedowns and Impairment data on file, last reported at $3.3 million in Q3 2013.
- Asset Writedowns and Impairment for Q3 2013 came in at $3.3 million, down 27.26% year-over-year; the trailing twelve-month figure through Sep 2013 was $14.6 million (changed N/A YoY), and the FY2021 annual result was $977000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment was little changed at $3.3 million in Q3 2013 per ALKS's latest filing, from $3.3 million in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $4.6 million in Q3 2012 and troughed at $3.3 million in Q1 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2013 | 3.35 Mn |
| Sep 30, 2013 | 3.35 Mn |
| Jun 30, 2013 | 3.35 Mn |
| Jun 30, 2013 | 3.35 Mn |
| Mar 31, 2013 | 3.35 Mn |
| Mar 31, 2013 | 3.35 Mn |
| Sep 30, 2012 | 4.60 Mn |
| Sep 30, 2012 | 4.60 Mn |